Holen Sie sich die Stockscreener-App
25.82
22.14%
4.68
Roivant Sciences Ltd Aktie (ROIV) Neueste Nachrichten
Looking At The Narrative For Roivant Sciences ROIV After 2026 Catalyst And Litigation Shifts - Yahoo Finance
Roivant Sciences stock rockets after brepocitinib Phase 2 win — what ROIV investors watch next - TechStock²
Lumentum, Woodward, And Teradyne Are Among the Top 10 Large-Cap Gainers Last Week (Feb. 2-Feb. 6): Are the Others in Your Portfolio? - Benzinga
Roivant signals multiple pivotal trial readouts and accelerates brepocitinib phase III launch in 2026 - MSN
Roivant Sciences (ROIV) Q3 Loss Of US$265.9 Million Tests Bullish Profitability Narrative - simplywall.st
Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday - TechStock²
Roivant Sciences Ltd. (NASDAQ:ROIV) Q3 2025 Earnings Call Transcript - Insider Monkey
Roivant Sciences (ROIV) Soars 19.4% as Pipeline Drugs Progress - Finviz
Roivant Sciences earnings missed by $0.07, revenue fell short of estimates - Investing.com South Africa
10 Easy Double-Digit Gainers - Insider Monkey
Roivant Sciences Q3 2026 Earnings Call Transcript - MarketBeat
Roivant: The Next Telavant Has Arrived With Brepocitinib's Blockbuster Data (Rating Upgrade) - Seeking Alpha
Roivant Sciences Q4 2025 slides: positive brepocitinib data drives pipeline momentum - Investing.com Nigeria
Roivant Sciences (ROIV) Is Up 19.4% After Advancing Phase 2 Pipeline Despite Wider Quarterly Loss - simplywall.st
Roivant Sciences Ltd (ROIV) Q3 2025 Earnings Call Highlights: Strategic Advances and Financial ... By GuruFocus - Investing.com Canada
Earnings call transcript: Roivant Sciences misses Q3 2026 estimates despite stock surge - Investing.com Nigeria
Why Is Roivant Stock Trading Higher Today?Roivant Sciences (NASDAQ:ROIV) - Benzinga
Roivant Sciences Q3 Earnings Call Highlights - Yahoo Finance
Immunovant Q3 Earnings Call Highlights - Yahoo Finance
ROIV: Strong phase II data for brepocitinib in cutaneous sarcoidosis; multiple pivotal readouts ahead - TradingView
Roivant Sciences Q4 2025 slides: positive brepocitinib data drives pipeline momentum By Investing.com - Investing.com South Africa
Roivant Sciences Stock Rises 17% Over Positive Data From Phase 2 Study Of Brepocitinib - Nasdaq
Roivant Sciences stock soars after positive cutaneous sarcoidosis trial data By Investing.com - Investing.com Australia
Pfizer-backed Priovant posts positive data for lead asset (PFE) - Seeking Alpha
Roivant Sciences Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2025 - marketscreener.com
Roivant Sciences Ltd. (ROIV) Reports Q3 Loss, Misses Revenue Estimates - Yahoo Finance
Priovant announces positive phase 2 results for brepocitinib in cutaneous sarcoidosis (Cs) - marketscreener.com
Roivant Sciences Ltd. SEC 10-Q Report - TradingView
Roivant Sciences Ltd. (ROIV) Misses Q3 EPS by 7c - StreetInsider
Roivant Sciences Swings to Fiscal Q3 Loss as Revenue Falls - marketscreener.com
Earnings Flash (ROIV) Roivant Sciences Posts Fiscal Q3 Net Loss $0.38 a Share, vs. FactSet Est of $0.30 Loss - marketscreener.com
Roivant Sciences Ltd. Reports Positive Phase 2 Results and Financial Performance for Q3 2025 - TradingView
Roivant Announces Positive Phase 2 Results for Brepocitinib in Cutaneous Sarcoidosis (CS) and Reports Financial Results for the Third Quarter Ended December 31, 2025 - The Manila Times
Roivant’s brepocitinib delivers rapid, sustained remissions in cutaneous sarcoidosis — first positive placebo-controlled trial - stocktitan.net
All eyes on Roivant earnings ahead of key drug trial readouts By Investing.com - Investing.com South Africa
All eyes on Roivant earnings ahead of key drug trial readouts - Investing.com Australia
Examining the Future: Roivant Sciences's Earnings Outlook - Benzinga
Understanding Momentum Shifts in (ROIV) - Stock Traders Daily
Short Interest in Roivant Sciences Ltd. (NASDAQ:ROIV) Increases By 25.3% - MarketBeat
Market Recap: Can Roivant Sciences Ltd sustain earnings growthJuly 2025 Patterns & Advanced Swing Trade Entry Alerts - baoquankhu1.vn
Movement Recap: Whats the fair value of Roivant Sciences Ltd stockMarket Sentiment Report & Technical Confirmation Trade Alerts - baoquankhu1.vn
Roivant Sciences Ltd. (NASDAQ:ROIV) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Roivant Sciences (ROIV) to Release Quarterly Earnings on Friday - MarketBeat
Is Roivant Sciences Ltd. benefiting from innovation trends2025 Retail Activity & Technical Buy Zone Confirmation - Mfd.ru
Revenue Check: Can Roivant Sciences Ltd generate free cash flowPortfolio Growth Summary & Weekly Watchlist of Top Performers - baoquankhu1.vn
Roivant Sciences: King Of The Vants Prepares To Drop Vantism In Search Of Greater Growth - Seeking Alpha
Roivant Sciences Ltd. (ROIV) Stock Analysis: Exploring the 19.57% Potential Upside in a High-Stakes Biotech Sector - DirectorsTalk Interviews
Avoiding Lag: Real-Time Signals in (ROIV) Movement - Stock Traders Daily
Y Intercept Hong Kong Ltd Buys 601,178 Shares of Roivant Sciences Ltd. $ROIV - MarketBeat
Roivant to Report Financial Results for the Third Quarter Ended December 31, 2025, and Provide Business Update on Friday, February 6, 2026 - marketscreener.com
Parkside Financial Bank & Trust Has $10.57 Million Holdings in Roivant Sciences Ltd. $ROIV - MarketBeat
Campbell & CO Investment Adviser LLC Sells 68,705 Shares of Roivant Sciences Ltd. $ROIV - MarketBeat
Growth Value: Will GOOS benefit from geopolitical trendsInflation Watch & Stepwise Entry/Exit Trade Alerts - baoquankhu1.vn
Sun Pharma Eyes Organon In What Could Be India Pharma's Biggest Cross-Border Deal: Report - Sahm
Aug Summary: Can Roivant Sciences Ltd lead its sector in growthJuly 2025 Rallies & Low Risk Growth Stock Ideas - baoquankhu1.vn
Roivant Sciences Insider Sold Shares Worth $4,384,000, According to a Recent SEC Filing - marketscreener.com
Roivant Sciences(ROIV.US) Officer Sells US$4.38 Million in Common Stock - 富途牛牛
Roivant Sciences (NASDAQ:ROIV) CEO Eric Venker Sells 200,000 Shares - MarketBeat
Profit Review: What is the dividend yield of Roivant Sciences LtdMarket Trend Review & Low Risk Entry Point Guides - baoquankhu1.vn
Is Roivant Sciences Ltd forming a bullish divergenceJuly 2025 Technicals & Long-Term Growth Stock Strategies - baoquankhu1.vn
Roivant Sciences stock hits all-time high of $23.47 By Investing.com - Investing.com Nigeria
US Market Wrap: Does Roivant Sciences Ltd stock trade at a discount to peers2025 Technical Overview & Stepwise Entry and Exit Trade Signals - Bộ Nội Vụ
0.23%
1.25%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):